American Pharmacists Association

About: American Pharmacists Association is a other organization based out in Washington D.C., District of Columbia, United States. It is known for research contribution in the topics: Pharmacist & Pharmacy. The organization has 2413 authors who have published 1969 publications receiving 30470 citations. The organization is also known as: APhA & American Pharmaceutical Association.

Product Monographs Supplied by Drug Manufacturers to Community Pharmacists in Spain

Abstract: Dispos 1998,26:257-60. 3 . Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985;37:249-63. 4. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med 1976;294:1104-6. 5 . Rainey PM, McCance EF, Mitchel SM, Jatlow P, Andrews L, Friedland G. Interaction of methadone with didanosine and stavudine (abstract). Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31–February 4, 1999. 6 . Patel SS, Benfield P. Nevirapine. Clin Immunother 1996;6:307-17. 7 . Altice FL, Friedland GH, Coouney E. Nevirapine-induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999;8:957-62. 8. Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 1999;8:1004-5. 9 . Tashima K, Bose T, Gormley J, Sousa H, Flanigan TP. The potential impact of efavirenz on methadone maintenance (abstract). Presented at the 9th European Conference of Clinical Microbiology and Infectious Diseases. Berlin, Germany, March 21–24, 1999.

Extended stability of intravenous acetaminophen in syringes and opened vials.

Abstract: Purpose The stability of i.v. acetaminophen beyond the manufacturer-recommended usage limit of six hours for opened vials was evaluated. Methods Intravenous acetaminophen (10 mg/mL) was obtained. Three identical samples of 100 mg (10 mL in a 10-mL syringe), 250 mg (25 mL in a 30-mL syringe), 500 mg (50 mL in a 60-mL syringe), 250 mg (25 mL in the original vial), and 900 mg (90 mL in original vial) were prepared. A 0.5-mL volume of each sample was withdrawn, diluted with mobile phase to an expected concentration of 50 μg/mL, and assayed in duplicate using high-performance liquid chromatography immediately after preparation and at 24, 48, 72, and 84 hours. The samples were visually inspected for any change in color, and pH was assessed at each time of analysis. The stability of the solutions was determined by calculating the percentage of the initial acetaminophen concentration remaining at each test hour. Stability was defined as the retention of at least 90% of the initial acetaminophen concentration. Results At least 99% of the initial concentration of acetaminophen remained in the original vials and polypropylene syringes throughout the 84-hour study period. There were no detectable changes in color, pH, visible microbial growth, or visible drug precipitation. Conclusion Intravenous acetaminophen (10 mg/mL) was physically and chemically stable in a range of volumes for up to 84 hours in the opened vials and in polypropylene syringes at room temperature. Am J Health-Syst Pharm. 2012; 69:1999-2001

Stability of cysteamine hydrochloride in solution

Abstract: Summary Cysteamine hydrochloride injection has frequently been prescribed for the treatment of paracetamol overdosage. Since there was no satisfactory preparation available, investigations were conducted to formulate Cysteamine hydrochloride as a stable injection. A formula for a stable injection of Cysteamine hydrochloride is presented.

Improving medication therapy management through collaborative hospice care in rural Minnesota

Abstract: Objective To evaluate expanded pharmacy services designed to improve medication therapy management for hospice care in rural Minnesota. Methods Deidentified data were obtained from records kept by the study pharmacy as part of its normal operations. In-depth interviews of key pharmacy personnel and from each hospice care organization were conducted to identify overall themes based on their experiences. Descriptive analysis was conducted for summarizing the findings. Information gleaned from the interviews was documented and themes identified. These themes were used to provide insight for those who may wish to adopt this program for their patient populations. Results At initial enrollment into hospice care, 85% of the patients received at least one recommendation related to their medication therapy. During patients’ enrollment in hospice care, the most common types of problems addressed through pharmacist consults were symptom control (65%), followed by dosage form (15%), medication management (12%), and adverse effect control (8%). Conclusion Implementation and evaluation of this program showed that the structures and processes used were sound and could be transferred to other patient populations. Outcomes from the program were favorable from practitioner, organization, and patient care perspectives.

Delayed treatment of vindesine extravasation.

Abstract: membrane, surface area of 0.8 m2, and ultrafiltration coefficient rate of 4.2 mUmin. Immediatelyupon completionof dialysisa third bloodsamplewas taken. Samples were then analyzed in triplicate as described by Badcock and Zoanetti,\"Clobazam and N-desmethylclobazamwere extracted from serum with ethyl acetate,and theirconcentrations were determinedusing a Varian3500 capillary gas chromatograph (Varian, Walnut Creek, CAl equipped with a 63Ni electron-capture detector.Methylclonazepam was used as an internalstandard.The intraassaycoefficientof variationfor the assay had been calculatedpreviouslyas 4.1 percent for clobazam (n=21) and 3.7 percent for N-desmethylclobazam (n=21) over a range that included the concentrations found in our patient. Doseand weight-adjusted serumconcentrations are presentedin Table 1.2.4 Data are taken from adults with normal renal function on chronic clobazam therapy who were also receiving concurrent valproate sodium. The large interpatient variations become obvious when the drug concentrations in these two studies are compared. Dose-adjusted serum concentrations of both clobazarn and N-desmethylclobazam in our patient appear to be consistent with those determined by these investigators. Calculation of clobazam half-lives has been excluded. We consider this calculation to be inappropriate, given the scarcity of data points and the short time span of measurements relative to the probable half-life. However, it is apparent that dialysis had little or no effect on drug concentrations and is not a clinical consideration. Clobazam and N-desmethylclobazarn concentrations were consistent with those seen in renally healthy subjects during both a normal dosing interval and in hemodialysis. Although we studied only one patient, the resulting serum concentrations of clobazarn and N-desmethylclobazarn indicate there is no necessity to alter clobazam doses in any degree of renal failure, nor are concentrations markedly altered by hemodialysis.